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Urinary excretion of aquaporin-2 water channel exaggerated
dependent upon vasopressin in congestive heart failure.
Background. Impaired water excretion occurs in patients
with congestive heart failure. The present study was under-
taken to determine whether urinary excretion of aquaporin-2
(AQP-2) water channel is exaggerated in patients with conges-
tive heart failure dependent upon arginine vasopressin (AVP).
Methods. Sixty-five patients with congestive heart failure and
eight age- and gender-matched control subjects were exam-
ined. The patients were divided into four groups according to
the criteria of New York Heart Association (NYHA). Plasma
AVP levels, urinary excretion of AQP-2, and cardiac index were
determined.
Results. Plasma AVP levels were progressively increased fol-
lowing the severity of NYHA class in the patients with conges-
tive heart failure. Cardiac index was inversely decreased, and
there was a negative correlation between plasma AVP levels
and cardiac index (r = −0.430, P < 0.02). Urinary excretion
of AQP-2 was 187.3 ± 50.2 fmol/mg creatinine in the control
subjects. It was markedly increased in the patients. Urinary ex-
cretion of AQP-2 was elevated to 1144.4 ± 257.5 and 990.5 ±
176.0 fmol/mg creatinine in the patients with NYHA class III
and class IV, respectively, values significantly greater than the
control subjects (P < 0.05). Urinary excretion of AQP-2 had
a positive correlation with plasma AVP levels (r = 0.280, P <
0.02).
Conclusion. The present study indicates that exaggerated
urinary excretion of AQP-2 is dependent on baroreceptor-
mediated release of AVP in patients with congestive heart
failure.
Impaired water excretion occurs in patients with con-
gestive heart failure [1, 2]. In these clinical settings
there is hypervolemic hyponatremia to various extents.
Baroreceptor-mediated, nonsuppressible release of argi-
nine vasopressin (AVP) is found despite hypo-osmolality,
1See Editorial by Gross, p. 1707.
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which should reduce AVP release to undetectable levels
[3–7]. The administration of AVP V2 receptor antagonists
determined the involvement of AVP in the impairment
in water excretion in rats with heart failure [8, 9].
Aquaporin-2 (AQP-2) is an AVP-regulated water
channel of collecting duct cells [10, 11]. In response to
AVP, AQP-2 is translocated from cytoplasmic vesicles
to apical plasma membranes, and increases water per-
meability [12–14]. Exogenous and endogenous AVP in-
creases the expression of AQP-2 mRNA in the kidney
[11, 12, 15, 16]. AQP-2 is in part excreted into the urine
[17], which is measurable by radioimmunoassay (RIA),
Western blot, and enzyme-linked immunosorbent assay
(ELISA) using a specific antibody against AQP-2 [17–19].
There is a positive correlation between plasma AVP levels
and urinary excretion of AQP-2 in normal subjects [20].
Augmentation in urinary excretion of AQP-2 is found
in various disorders of impaired water excretion, includ-
ing syndrome of inappropriate secretion of antidiuretic
hormone (SIADH), hypopituitarism, mineralocorticoid-
responsive hyponatremia of the elderly (MRHE), liver
cirrhosis, and heart failure [21–25].
The present study was undretaken to determine
whether urinary excretion of AQP-2 is increased in pa-
tients with congestive heart failure. Furthermore, the
relationship between plasma AVP levels and urinary ex-
cretion of AQP-2 was analyzed.
METHODS
Subjects
Sixty-five patients with congestive heart failure were
examined from January 2002 to December 2003. They
were 51 males and 14 females, with the ages ranging
from 30 to 83 years (62.0 ± 12.0 years, mean ± SD). Be-
cause of varying symptoms closely linked to congestive
heart failure the patients were admitted to the Cardiac
Care Unit and the Cardiovascular Ward of Jichi Med-
ical School Omiya Medical Center. The patients were
divided into four subgroups according to the criteria of
New York Heart Association (NYHA): NYHA class I,
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15 patients; NYHA class II, 17 patients; NYHA class III,
15 patients; and NYHA class IV, 18 patients. The
patients included acute and chronic heart failure and
acute exacerbation of chronic heart failure; that is, five
patients with hypertensive heart failure, 20 patients with
ischemic heart disease, 15 patients with dilated cardiomy-
opathy, six patients with valvular disease, and 13 patients
with miscellaneous causes. Sixteen patients had diabetes
mellitus. However, patients with congestive heart failure
were excluded if they had complicated with other ede-
matous diseases or advanced renal diseases with serum
creatinine levels more than 176.8 lmol/L. After the hospi-
talization, ultrasonic cardiogram was examined in all the
patients, and Swan-Ganz catheterization was carried out
in 30 of 65 patients to determine the cardiac hemodynam-
ics. Eight age- and gender-matched control subjects (39 to
75 years) served as a control. On the admission, blood col-
lections were made to determine serum sodium, plasma
osmolality, and plasma AVP concentration while the sub-
jects rested recumbent on the bed. Two-hour urine col-
lections were made through bladder catheter to measure
urinary osmolality, urine creatinine, and urinary excre-
tion of AQP-2. The present study was approved by the
Ethical Committee of Jichi Medical School for Human
Study. We obtained informed consent from the subjects
who joined into the present protocol.
Measurements
Blood was collected in chilled tubes containing
ethylenediaminetetraacetic acid (EDTA)-Na2 (1 mg per
mL blood) and centrifuged at 3000 rpm at 4◦C for 15
minutes. The supernatants were decanted and frozen at
−20◦C until the time of assay for plasma AVP. The col-
lected urine samples were also frozen at –20◦C until the
time of assay for AQP-2. Plasma AVP was measured by
RIA using AVP RIA kits (Mitsubishi Chemistry, Tokyo,
Japan) [8]. AQP-2 was measured by ELISA [19, 21].
Plasma osmolality and urine osmolality were measured
by freezing-point depression (Model 3W2) (Advanced
Instruments, Needham Height, MA, USA). The normal
value of plasma AVP is 0.2 to 2.2 pmol/L. That of urinary
excretion of AQP-2 is 153.3 ± 28.1 fmol/mg creatinine.
Statistical analysis
All values were expressed as the means ± SEM. They
were analyzed by Fisher’s t test to compare the difference.
Simple linear regression analysis was performed to calcu-
late correlations. The statistical package of StatView was
employed for the present analysis. A P value of less than
0.05 was considered significant.
RESULTS
Table 1 shows serum sodium, plasma osmolality, urine
osmolality and others in the patients with congestive
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Fig. 1. Plasma arginine vasopressin (AVP) levels (A) and cardiac in-
dex (B) in the patients with congestive heart failure and in the control
subjects. The number of subjects was shown in each group in bracket.
∗P < 0.05 and ∗∗P < 0.0001 vs. the control group; #P < 0.05, ##P < 0.001
and ###P < 0.0001 vs. the NYHA class I group. Values are mean ± SEM.
heart failure and the control subjects. Both serum sodium
and plasma osmolality seemed likely to decrease follow-
ing the upper classes of NYHA, but they were not statis-
tically different from those in the control subjects. Also,
there was no difference in urine osmolality among all the
groups. The ratio of urine osmolality/plasma osmolality
was not significantly different among any subgroup (data
not shown). In most of the patients with NYHA class
III and class IV medication with several drugs, including
diuretics, had been performed persistently, and thus this
may affect the present results at the hospitalization.
Plasma AVP levels and cardiac index in the patients
with congestive heart failure and the control subjects are
depicted in Figure 1. Plasma AVP levels were increased
gradually in association with the upper classes of NYHA
in the patients. The levels were elevated to 17.2 ± 3.5
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Fig. 2. Urinary excretion of aquaporin-2 (UAQP-2) in the patients with
congestive heart failure and in the control subjects. The number of
subjects was shown in each group in bracket. ∗P < 0.01 and ∗∗P < 0.02
vs. the control group. Values are mean ± SEM.
and 29.4 ± 5.8 pmol/L in the subgroups of NYHA class
III and class IV, respectively, values significantly higher
than that in the control subjects (P < 0.05). Cardiac in-
dex was gradually decreased according to the severity
of NYHA class (Fig. 1). Plasma AVP levels had a neg-
ative correlation with the cardiac index (r = −0.430,
P < 0.02). We also determined pulmonary capillary
wedge pressure (PCWP) and central venous pressure
(CVP) in the patients. Both PCWP and CVP became
greater according to the upper classes of NYHA (data
not shown). However, there was no significant correla-
tion between plasma AVP levels and PCWP (r = 0.260,
P = 0.126), and between plasma AVP levels and CVP
(r = 0.190, P = 0.345).
Figure 2 shows urinary excretion of AQP-2 in the
patients with congestive heart failure and the control
subjects. In the control subjects urinary excretion of
AQP-2 was 187.3 ± 50.2 fmol/mg creatinine. It was re-
markably increased in the patients with congestive heart
failure. Urinary excretion of AQP-2 was 1144.4 ± 257.5
and 990.5 ± 176.0 fmol/mg creatinine in the subgroups of
NYHA class III and class IV, respectively, which were
significantly greater than that in the control subjects
(P < 0.02).
Figure 3 depicts the relationship between plasma AVP
levels and urinary excretion of AQP-2 in the patients with
congestive heart failure. Urinary excretion of AQP-2 had
a positive correlation with plasma AVP levels (r = 0.280,
P < 0.02). The analysis was also carried out excluding the
patients with NYHA class IV, because varying pathologic
and/or medicating factors might influence the condition
in those with NYHA class IV. Again, the positive cor-
relation between them was evident and its significance
became greater (r = 0.328, P < 0.02). However, urinary
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Fig. 3. Relationship between plasma arginine vasopressin (AVP) levels
and urinary excretion of aquaporin-2 (UAQP-2) in the patients with
congestive heart failure. There is a positive correlation (r = 0.280, P <
0.02).
excretion of AQP-2 did not correlate with urinary sodium
excretion and urine osmolality (data not shown).
Table 2 shows the changes in serum sodium, plasma
osmolality, plasma AVP, urinary excretion of AQP-2,
and cardiac index in the congestive heart failure patients
with NYHA class III and class IV, in whom Swan-Ganz
catheterization was carried out at the initial periods of
hospitalization. Serum sodium and plasma osmolality did
not alter statistically during the catheter insertion. Both
plasma AVP levels and urinary excretion of AQP-2 were
markedly reduced, and they were further decreased to
4.7 ± 0.9 pmol/L and 215.0 ± 54.5 fmol/mg creatinine at
the discharge, respectively. Inversely, the cardiac index
was significantly increased from 2.1 ± 0.1 to 2.9 ± 0.2 L/
min/m2 (P < 0.001).
DISCUSSION
The present study clearly demonstrated that urinary
excretion of AQP-2 was exaggerated in the patients with
congestive heart failure compared with that in the con-
trol subjects. The more increase in urinary excretion of
AQP-2 was found in the patients with more severe grade
of NYHA class. The alteration was closely in concert with
the elevation of plasma AVP levels. However, we could
not show severe hyponatremia and hypoosmolality in the
patients with congestive heart failure despite of nonsup-
pressible release of AVP.
Clinical and laboratory experiments have demon-
strated that impaired ability to excrete a water load in
patients with congestive heart failure [1, 2, 26]. Persistent
elevation of plasma AVP levels has been shown despite
hypo-osmolality, which should suppress the osmotic re-
lease of AVP [3–8, 27]. These pathologic states are linked
to hyponatremia to a various extent. RIA technique en-
ables us to reliably measure plasma AVP levels. In most
clinical settings nonsuppressible levels of plasma AVP
are estimated to be relatively high as compared to the re-
duced plasma osmolality [1–8]. In the present study the
plasma AVP levels reached extraordinary high levels in
the patients with congestive heart failure. The elevation
of AVP release was closely associated with the afferent
pathways of baroreceptors, which was stimulated by re-
duced effective circulatory blood volume [1–8]. Plasma
AVP levels had a negative correlation with the cardiac
index. As most of patients in NYHA class III and class IV
took diuretics, it is possible that this diuretic therapy may
increase the excretion of diluted urine and further stim-
ulate AVP secretion. We wonder the elevation of plasma
AVP could be involved in cardiac derangement through
V1a receptors as well as V2 receptors in congestive heart
failure. In fact, the recent study showed that the admin-
istration of nonpeptide V1a and V2 receptor antagonist
preserves cardiac function in congestive heart failure [28].
The present study further demonstrated exaggerated
urinary excretion of AQP-2 in the patients with con-
gestive heart failure. AQP-2 is the AVP-regulated wa-
ter channel of collecting duct cells [10, 11]. Short-term
regulation by AVP means that AQP-2 has cellular traf-
ficking from the cytoplasmic vesicles to the apical plasma
membranes; and vice versa after withdrawal of AVP stim-
ulation [12–14, 29]. Long-term regulation means that
AVP also regulates transcription and protein synthesis of
AQP-2 [11, 12, 15, 29]. Recently, we clarified that AQP-2
is partly excreted into the urine, which is approximately
3% of AQP-2 in the collecting duct cells [17, 30]. There is
no difference in urinary excretion of AQP-2 among the
varying ages, ranging 24 to 76 years [30]. There were posi-
tive correlations between plasma AVP levels and urinary
excretion of AQP-2 in the patients with congestive heart
failure as well as in normal subjects [20]. In the patients
with congestive heart failure, urinary excretion of AQP-2
was not progressively increased in concert with the grade
of NYHA. The levels were somewhat low in the class IV
compared with the class III. We may consider that recep-
tor occupancy of AVP affected the V2 action in the kid-
ney. Also, renal damage caused by lowered organ blood
supply, as well as a series of intensive therapy might af-
fect urinary excretion of AQP-2 in severe patients with
NYHA class IV. There were heterogenous patients with
congestive heart failure, and they influenced no finding
of hyponatremia resulted from altered impairment in wa-
ter excretion. In fact, most of patients had already treated
with several drugs, including loop diuretics, antihyperten-
sive agents, and so on before the admission. The finding
of the exaggerated urinary excretion of AQP-2 may be
tightly linked with the up-regulation of AQP-2 mRNA
expression in the kidneys in the experimental models of
congestive heart failure [31, 32]. There are only two re-
ports regarding urinary excretion of AQP-2 in conges-
tive heart failure [22, 25]. Martin et al [22] reported that
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Table 2. Changes in serum sodium, modified plasma osmolality, plasma arginine vasopressin (AVP), urinary excretion of aquaporin-2 (UAQP-2)
and cardiac index in the New York Heart Association (NYHA) class III and class IV patients with congestive heart failure
Serum sodium Modified plasma Plasma AVP UAQP-2 fmol/mg Cardiac index
mmol/L osmolality mmol/kg pmol/L creatinine L/min/m2
Swan-Ganz
catheter
Insertion 141.0 ± 1.0 (21) 294.1 ± 1.1 (21) 25.3 ± 5.5 (21) 1008.3 ± 213.6 (17) 2.2 ± 0.1 (18)
Removal 141.9 ± 0.6 (21) 294.8 ± 1.2 (21) 7.2 ± 1.1 (21) 527.2 ± 155.2 (17) 2.9 ± 0.2 (18)
P value NS NS <0.01 <0.05 <0.001
Modified plasma osmolality means the plasma osmolality, in which blood glucose level was calculated as 5.5 mmol/L in the diabetic patients. The number of patients
was shown in parentheses. Values are means ± SEM.
percent decrease in urinary excretion of AQP-2 was
found in patients after administering the nonpeptide AVP
receptor antagonist. Petersen et al [25] showed an in-
crease in excretion of AQP-2 in urine in patients with con-
gestive heart failure, which was suppressed by an acute
water load. In contrast, urinary AQP-2 excretion is ele-
vated independently of plasma AVP in patients with liver
cirrhosis [33]. The circulatory distress of decreased effec-
tive circulatory blood volume is similarly found in liver
cirrhosis as well as congestive heart failure, which acti-
vates afferent baroreceptor pathway. The possible mech-
anism to make this difference could not be elucidated and
further study will be needed.
As noted earlier, urinary excretion of AQP-2 was
closely in concert with plasma AVP levels in the pa-
tients with congestive heart failure. Similar results were
obtained with disorders of impaired water excretion,
such as SIADH, hypopituitarism, and MRHE [21, 24].
Enhancement in urinary excretion of AQP-2 is derived
from the augmented antidiuretic action of AVP. However,
maximal increase in plasma AVP levels in the patients
with NYHA class IV was not associated with urinary
excretion of AQP-2, because it was not the greatest in the
NYHA class IV patients. This alteration could be inter-
preted by several possibilities. First, there might be renal
escape from AVP-induced antidiuresis [34, 35]. In the ex-
perimental SIADH rats the attenuated up-regulation of
AQP-2 gene leads to the decrease in urinary concentrat-
ing ability [34, 35]. Second, renal tubular damage due to
lowered organ blood supply might reduce the expressed
AQP-2 in collecting duct cells in the NYHA class IV pa-
tients. Third, intensive therapies before and after the ad-
mission might alter either AVP release or renal response
to AVP. In addition, we could not find a relationship be-
tween urine osmolality and urinary excretion of AQP-2.
There were some reasons. The 2-hour urine collection
was made at hospitalization to measure urine osmolal-
ity and urinary excretion of AQP-2. The patients with
NYHA class III and class IV had taken loop diuretics and
other drugs before the emergency admission. Also, the
intensive therapy for congestive heart failure was started
immediately after the hospitalization in these patients.
These treatments may affect the urinary parameters,
and the relation of urinary AQP-2 excretion to urinary
osmolality, though urinary AQP-2 excretion shows pos-
itive correlation with urinary osmolality in normal vol-
unteers [30]. The alterations during therapeutic period
were found in the patients with NYHA class III and class
IV, in whom Swan-Ganz catheter was inserted. Urinary
excretion of AQP-2 was markedly decreased in concert
with the reduction in plasma AVP levels. It was further
decreased to 215.0 fmol/mg creatinine (mean) at the dis-
charge, that is, close to the normal range. This finding
during the therapeutic period strengthened the profound
relation between plasma AVP levels and urinary excre-
tion of AQP-2 in congestive heart failure.
CONCLUSION
We demonstrated that exaggerated urinary excretion
of AQP-2 was found in the patients with congestive heart
failure. The extraordinary high levels of plasma AVP in
the NYHA class IV patients could produce renal escape
from AVP-induced antidiuresis, and might be involved in
cardiac derangement directly through V1a receptors. The
present findings indicate that urinary excretion of AQP-
2 is increased dependent upon baroreceptor-mediated
AVP release in the patients with congestive heart failure.
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